Patent SG-11201408652S-A (SG)
Title: Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
Inventor: RÖDER JOANNA
IPC: G01N33/574
Filed: 2013-03-15
Abstract: (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 3 January 2014 (03.01.2014) WIPOIPCT (10) International Publication Number WO 2014/003853 A1 (51) International Patent Classification: G01N33/68 (2006.01) G01N33/574 (2006.01) (21) International Application Number: (74) Agent: HILLMAN, Lisa, M., W.; McDonnell Boehnen Hulbert & Berghoff LLP, 300 South Wacker Drive, Chica­ go, IL 60606 (US). (22) International Filing Date: (25) Filing Language: (26) Publication Language: (30) Priority Data: 61/664,329 61/664,308 26 June 2012 (26.06.2012) 26 June 2012 (26.06.2012) (71) Applicants (for all designated States except US): BIODESIX, INC. [US/US]; 2970 Wilderness Place, Suite 100, Boulder, CO 80301 (US). GLOBEIMMUNE, INC. [US/US]; 1450 Infinite Drive, Louisville, CO 80027 (US). (72) Inventors; and (71) Applicants (for US only)-. RODER, Joanna [GB/US]; 22105 W. Whitewood Drive, Steamboat Springs, CO 80487 (US). RODER, Heinrich [DE/US]; 22105 W. Whitewood Drive, Steamboat Springs, CO 80487 (US). PCT/US2013/032024 (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 15 March 2013 (15.03.2013) English English US US (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, [Continued on next page] (54) Title: MASS-SPECTRAL METHOD FOR SELECTION, AND DE-SELECTION, OF CANCER PATIENTS FOR TREAT­ MENT WITH IMMUNE RESPONSE GENERATING THERAPIES Fig. 11 oo m o o o CJ O & (57) Abstract: A method and system for predicting in advance of treatment whether a cancer patient is likely, or not likely, to obtain benefit from admin­ istration of a yeast-based immune response generating therapy, which may be yeast-based immunotherapy for mutated Ras-based cancer, alone or in com­ bination with another anti-cancer therapy. The method uses mass spectro­ metry of blood-derived a patient sample and a computer configured as a clas­ sifier using a naming set of class-labeled spectra from other cancer patients that either benefitted or did not benefit from an immune response generating therapy alone or in combination with another anti-cancer therapy. Also dis - closed are methods of treatment of a cancer patient, comprising administer­ ing yeast-based immune response generating therapy, which may a be yeast- based immunotherapy for mutated Ras-based cancer, to a patient selected by a test in accordance with predictive mass spectral methods disclosed herein, in which the class label for the spectra indicates the patient likely is to bene - fit from the yeast-based immunotherapy. WO 2014/003853 Al III llll IIII III III Hill III III III Hill II llll lllll llll 111 mill llll 111 llll TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, , , , . t , nn y , ML, MR, NE, SN, TD, TG). ~ wrth amended clarms (Art. 19(1)) — with sequence listing part of description (Rule 5.2(a)) Published: — with international search report (Art. 21(3))